Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in The Aesthetic Meeting 2022 from April 20-24 in San Diego, California. Dr. Caroline Glicksman will present an update on the Motiva US Core Clinical Study on April 21 at 3:50pm PT. The company will also host an event honoring Dr. Brian Kinney's contributions to plastic surgery and women's health. Established in 2010, Establishment Labs specializes in breast aesthetics and reconstruction, delivering approximately 2.0 million Motiva Implants in over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leader in women's health technology, announced that CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:10 PM Eastern Time. A live webcast of the presentation can be accessed on the Establishment Labs investor relations website, with an archived version available afterward. The company specializes in breast aesthetics, offering Motiva Implants® and related products that have been delivered to over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported fourth-quarter 2021 revenue of $35.3 million, up 31% year-over-year, achieving a new quarterly record. The full-year revenue totaled $126.7 million, a 50% increase. Fourth-quarter gross profit was 68.6% of revenue, significantly higher than 54.3%% in 2020. For 2022, the company projects revenue of $155 million to $165 million, reflecting a 22% to 30% growth. However, operating expenses increased by 48.2% to $33.6 million.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has achieved a significant milestone by surpassing two million Motiva Implants in the market. This achievement reflects a steady growth trajectory, with the company delivering one million implants in the first seven years and doubling that in just two years. The implants maintain an impressive less than 1% clinical complication rate, showcasing their safety and effectiveness. Operating in over 80 countries, Establishment Labs is committed to innovation in breast aesthetics and reconstruction, aiming to raise standards in women's health.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for the quarter ending December 31, 2021, on March 1, 2022, before market opens. The company will host a conference call at 8:30 am ET the same day to discuss these results. Established in 2010, the company focuses on women’s health, particularly breast aesthetics and reconstruction, offering innovative silicone gel-filled Motiva Implants®. Over 2 million of these implants have been distributed across 80 countries, emphasizing its global presence and commitment to advanced healthcare solutions.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported preliminary unaudited revenue for Q4 2021 expected between $35.0 million and $35.5 million, signifying a growth of 30% to 32% year-over-year. For the fiscal year 2021, the company anticipates revenue of $126.4 million to $126.9 million, reflecting a growth of 49% to 50% compared to 2020. The company will share its complete financial results on March 1, 2022.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global leader in women's health technology, has announced that CEO Juan José Chacón-Quirós will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible afterward. Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative Motiva Implants with over 1.8 million units delivered since 2010 across 80 countries.
Establishment Labs (NASDAQ: ESTA) has appointed Raj Denhoy as Chief Financial Officer, effective immediately. Denhoy, who joined the company in February 2021 and served as Interim CFO since August, has extensive experience in medical device research. CEO Juan José Chacón-Quirós highlighted Denhoy's understanding of the business and industry vision. Denhoy expressed optimism about the company's potential to lead in breast aesthetics and reconstruction, emphasizing innovation and stakeholder value.
Establishment Labs Holdings (NASDAQ: ESTA) announced the immediate appointment of Leslie Gillin to its Board of Directors, bringing extensive experience in consumer marketing and finance. CEO Juan José Chacón-Quirós expressed confidence in Gillin's ability to enhance patient engagement and innovative business models. Gillin, formerly of JPMorgan Chase and Citibank, aims to leverage the company’s unique technologies for improved patient experiences and expanded market presence. Established in 2010, Establishment Labs focuses on breast health with over 1.8 million Motiva Implants® sold globally.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the Stephens Annual Investment Conference from December 1-3, 2021. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will speak on December 2 at 1:00 pm CT. The presentation will be available via live webcast on the company's investor relations website, with an archived version accessible post-event. Establishment Labs focuses on women's health, providing innovative breast aesthetics solutions, including its Motiva Implants, with over 1.8 million units delivered since 2010.